+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

The Supreme Court just issued a big win for new drugs that could save the US billions

Aug 26, 2024, 07:37 IST
Thomson ReutersFlu vaccine drips out of a syringe as a nurse prepares for a patient at a clinic in central LondonWASHINGTON (Reuters) - The US Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs - known as biosimilars - to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

The justices, in a 9-0 ruling, overturned a lower court decision that had prevented Swiss pharmaceutical company Novartis from selling its copycat version of California-based Amgen's Neupogen until six months after the U.S. Food and Drug Administration approved it.

Biosimilars are a bit more complicated than your average competing medicine: Unlike generics for chemical-based drugs like antibiotics that can be interchangeable with branded versions, the copycats of biologic medications, produced using living cells, have a few more caveats.

As it stands right now, biosimilars can't be used interchangeably with branded versions, meaning if you were to get a prescription for a branded biologic, you wouldn't be able to opt for the "generic" one at the pharmacy as easily as you could if the drug was, say, a statin.

Advertisement

It also takes more time, energy, and money to get a biosimilar approved, compared to a generic medicine. To develop a biosimilar, it usually takes about eight years and can costs about $250 million. In comparison, a generic takes a quarter of that time (about two years) and costs a tenth of the price ($5 million) to produce.

Having more biosimilars on the market faster - without waiting six months - would be a big deal. It might be the best way to drive down the cost of biologic medications that have been around for a while. The savings of putting people on far less costly biosimilars - even just new patients who have never taken the original - are estimated to be billions of dollars. Express Scripts, a pharmacy benefit manager, estimated in 2013 that the US could be saving $250 billion over the next 10 years because of biosimilars.

Reuters reporting by Andrew Chung.

NOW WATCH: Economist: Climate change won't be the only major concern if Trump pulls out of the Paris Accord

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article